In, 2021, the FDA approved Tencentriq as an adjuvant treatment for patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved VENTANA PD-L1 (SP263) assay (Ventana Medical Systems, Inc.), following resection and platinum-based chemotherapy. The gene discussed is CD274; the disease is neoplasm.